Each year, a staggering 13 million adults across the country grapple with the weight of major depression. Among those seeking care, nearly 40% find no respite or full recovery through conventional antidepressant medications.
For those battling the relentless darkness of depression, Ketamine— initially used as an anesthesia medicine in the 1960s, represents a powerful tool in the fight against Major Depressive Disorder and Treatment Resistant Depression (TRD).
As delivered by a safe and supervised IV infusion, Ketamine has been demonstrated to promote the growth of new synapses in the prefrontal cortex and dampen the overactive parts of the brain associated with depression to offer a rapid antidepressant effect. The subject of extensive study over the past two decades, IV Ketamine treatment has been clinically proven to provide rapid, robust, and sustained antidepressant effects for many adults who are unresponsive to standard therapies, including SSRIs. Its track record of success has also led to the development of Spravato®, an Esketamine nasal spray.
Spravato®, approved by the. FDA in 2019 for use in conjunction with an oral antidepressant offers new hope for individuals with Major Depressive Disorder that is treatment-resistant or includes suicidal thoughts. More easily deliverable than IV Ketamine, Spravato® is an intranasal spray that harnesses the power of Esketamine, a potent ketamine derivative. As provided in a comfortable, supervised, and supportive in-office setting Spravato® offers rapid relief from depression symptoms while allowing the oral antidepressant medication to take effect.
Refer a patient, friend, or make the decision for yourself to feel better. Contact us today to set up an initial free consultation with an Intake Coordinator.
Duluth
St. Cloud